See more : Taiyen Biotech Co., Ltd. (1737.TW) Income Statement Analysis – Financial Results
Complete financial analysis of PepGen Inc. (PEPG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PepGen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Gjensidige Forsikring ASA (GJF.OL) Income Statement Analysis – Financial Results
- ZhongAn Online P & C Insurance Co., Ltd. (6060.HK) Income Statement Analysis – Financial Results
- Easylink Solutions Corp. (ESYL) Income Statement Analysis – Financial Results
- LAST MILE ENTERPRISES LIMITED (LASTMILE.BO) Income Statement Analysis – Financial Results
- Fennec Pharmaceuticals Inc. (FENC) Income Statement Analysis – Financial Results
PepGen Inc. (PEPG)
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
Gross Profit | -1.18M | -493.00K | -178.00K | -110.00K | -106.00K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 66.94M | 54.08M | 19.00M | 1.02M | 620.00K |
General & Administrative | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 627.37K |
SG&A | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
Other Expenses | 0.00 | 110.00K | -172.00K | -20.00K | 0.00 |
Operating Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.25M |
Cost & Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.35M |
Interest Income | 6.40M | 2.79M | 0.00 | 8.00K | 6.00K |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
EBITDA | -83.58M | -67.81M | -26.93M | -1.77M | -1.25M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -84.77M | -68.30M | -27.11M | -1.88M | -1.35M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 6.21M | 2.90M | -172.00K | -12.00K | 8.00K |
Income Before Tax | -78.55M | -65.40M | -27.28M | -1.89M | -1.35M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 73.00K | 3.71M | -58.56K | -8.00K | 0.00 |
Net Income | -78.63M | -69.10M | -27.28M | -1.88M | -1.35M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
EPS Diluted | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
Weighted Avg Shares Out | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
Weighted Avg Shares Out (Dil) | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
PepGen Inc. Is Being Investigated By The Schall Law Firm For Possible Securities Fraud And Investors Are Urged To Participate
The Schall Law Firm Invites Shareholders To Join An Inquiry Into PepGen Inc For Violating Securities Laws
PepGen Inc. Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Urged To Participate
The Schall Law Firm Is Looking Into PepGen Inc For Possible Securities Related Infractions And Stockholders Should Reach Out
PepGen Inc. May Have Violated Securities Laws And Affected Investors Are Encouraged To Take Part In The Schall Law Firm's Inquiry
The Schall Law Firm Urges Shareholders To Join An Investigation Into Whether PepGen Inc Committed Securities Fraud
The Schall Law Firm Is Looking Into PepGen Inc. For Possible Securities Law Infractions And Investors Are Invited To Lend A Hand
PepGen Inc May Have Committed Securities Fraud And Shareholders With Losses Should Join The Schall Law Firm's Inquiry
The Schall Law Firm Is Looking Into Whether PepGen, Inc. Acted Unlawfully And Impacted Individuals Can Partake In The Investigation
The Schall Law Firm Is Looking Into PepGen Inc.'s Possible Securities Related Infractions And Affected Investors Should Reach Out
Source: https://incomestatements.info
Category: Stock Reports